Biochemists Switch DNA Functions on and Off Using Light – SciTechDaily

Biochemists use protein engineering to transfer photocaging groups to DNA.

DNA (deoxyribonucleic acid) is the basis of life on earth. The function of DNA is to store all the genetic information, which an organism needs to develop, function and reproduce. It is essentially a biological instruction manual found in every cell.

Biochemists at the University of Mnster have now developed a strategy for controlling the biological functions of DNA with the aid of light. This enables researchers to better understand and control the different processes which take place in the cell for example epigenetics, the key chemical change and regulatory lever in DNA.

The results have been published in the journal Angewandte Chemie.

The cells functions depend on special molecules, the enzymes. Enzymes are proteins, which carry out chemical reactions in the cell. They help to synthesize metabolic products, make copies of the DNA molecules, convert energy for the cells activities, change DNA epigenetically and break down certain molecules.

A team of researchers headed by Prof. Andrea Rentmeister from the Institute of Biochemistry at the University of Mnster used a so-called enzymatic cascade reaction in order to understand and track these functions better. This sequence of successive reaction steps involving different enzymes makes it possible to transfer so-called photocaging groups chemical groups, which can be removed by means of irradiation with light to DNA. Previously, studies had shown that only small residues (small modifications such as methyl groups) could be transferred very selectively to DNA, RNA (ribonucleic acid) or proteins.

As a result of our work, it is now possible to transfer larger residues or modifications such as the photocaging groups just mentioned, explains Nils Klcker, one of the lead authors of the study and a PhD student at the Institute of Biochemistry. Working together with structural biologist Prof. Daniel Kmmel, who also works at the Institute of Biochemistry, it was also possible to explain the basis for the changed activity at a molecular level.

Using so-called protein engineering a method for which a Nobel prize was awarded in 2018 the Mnster researchers engineered one enzyme in the cascade, making it possible to switch DNA functions on and off by means of light. With the aid of protein design, it was possible to expand the substrate spectrum of enzymes in this case, methionine adenosyltransferases (MATs). In their work, the researchers examined two MATs. The modifications carried out offer a starting point for developing other MATs with an expanded substrate spectrum.

Combining these MATs with other enzymes has potential for future cellular applications. This is an important step for implementing in-situ generated, non-natural substances for other enzymes in epigenetic studies, says Andrea Rentmeister.

Reference: Engineered SAM Synthetases for Enzymatic Generation of AdoMet Analogs with Photocaging Groups and Reversible DNA Modification in Cascade Reactions by Dr. Freideriki Michailidou, Nils Klcker, Nicolas V. Cornelissen, Dr. Rohit K. Singh, Aileen Peters, Anna Ovcharenko, Prof.Dr. Daniel Kmmel and Prof.Dr. Andrea Rentmeister, 5 October 2020, Angewandte Chemie.DOI: 10.1002/anie.202012623

Funding: The study received financial support from the German Research Foundation (DFG), the European Research Council (ERC) and the IRTG Mnster-Toronto network.

See the original post:
Biochemists Switch DNA Functions on and Off Using Light - SciTechDaily

Itaconic Acid Market Will Create New Growth Outlook In The Next Coming Years | Itaconix Corporation, Alpha Chemika, Thermo Fisher Scientific., Merck…

Itaconic Acid Market research analysis is one of the best ways that answers business challenges more quickly and also saves your lot of time. The study of this market research report covers a market attractiveness analysis, wherein each segment is targeted based on its market size, growth rate, and general attractiveness. This market research report is generated by taking into account a range of objectives of market research that are vital for the clients success. Moreover, big sample sizes are used for the data collection which suits the need of small, medium as well as large size of businesses.

Request Sample Copy of this research study at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-itaconic-acid-market

The top key players profiled in this report include:Itaconix Corporation, Qingdao Kehai Biochemistry Co., LTD., Zhejiang Guoguang Biochemistry Co.,Ltd., Alpha Chemika, AEKYUNG PETROCHEMICAL Co., Ltd, Ronas Chemicals Ind. Co., Ltd., Ultimate Chem India Pvt. Ltd, Choice Organochem Llp., FUSO CHEMICAL CO., LTD., Alfa Aesar, Thermo Fisher Scientific., Merck KGaA, Henan Haofei Chemical Co.,Ltd., Haihang Industry Co., Ltd, Hefei TNJ Chemical Industry Co.,Ltd., Spectrum Chemical Manufacturing Corp, FUJIFILM Wako Pure Chemical Corporation, among other.

Global Itaconic Acid Market Scenario

Itaconic acid market is expected to reach USD 127.04 million by 2027 growing at a growth rate of 4.20% in the forecast period 2020 to 2027. Increasing usage in agricultural applications and advancement in the bio- based PMMA are the factor for the market growth.

The COVID-19 pandemic has affected every aspect of life worldwide. The pandemic has affected every segment of the market, along with bringing disruption in the supply chain, demands & trends, and financial difficulties. The report covers the initial and future assessment of the COVID-19 impact on the market.

Global Itaconic Acid Market Outlook:

Itaconic acid is colorless crystalline carboxylic acid which usually develops naturally. They are usually non-toxic in nature and are biodegradable. They are widely used in application such as synthetic latex, cheland dispersant agent, unstable polyester resin, detergent builder, methyl methacrylate and SBR latex.

Growing prevalence for bio-based unsaturated polyester resin and rising awareness about the benefits of itaconic acid are the factor which is positively affecting the market growth. Increasing popularity of sustainable products will also propel the market growth. Itaconic acid is an organic compound that can be easily degraded and does not pose a threat to the environment; which is another factor contributing to drive its growth in the market. Increasing R& D investment to produce more innovative product will further create new opportunities for this market to grow in the forecast period of 2020- 2027.

Which Important Market Factors Are Explained In The Report?

This market report has been mainly designed by keeping in mind the customer requirements which will ultimately assist them in boosting their return on investment (ROI). Furthermore, this research report takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company. The data, information, statistics, facts and figures covered in the Itaconic Acid report lends a hand to industry in maximizing or minimizing the production of goods depending on the conditions of demand.

The Itaconic Acid Market segments and Market Data Break Down are illuminated below:

By Derivative (Styrene Butadiene Itaconic Acid, Methyl Methacrylate, Polyitaconic Acid, Others)

Application (SBR Latex, Synthetic Latex, Chillant Dispersant Agent, Superabsorbent Polymer, Unsaturated Polyester Resins, Methyl Methacrylate, Detergent Builder, Others)

Have Any Query Speak to Analyst @ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-itaconic-acid-market

Focal Points of the Report:

Market Coverage: This section of the report gives a detailed account of the key manufacturers, market segments, product scope, product range, forecast period, and application landscape.

Executive Summary: This chapter focuses on the market growth rate, significant market drivers and restraints, current market trends, and competitive outlook.

Regional Analysis: This section delves into the latest import and export trends of the market, production and consumption ratio, the leading market players in each region, and revenue generation.

Manufacturers Portfolio: Complete portfolios of all the local and global manufacturers, along with the SWOT analysis, production value and capacity, product catalogue, and other important details of their businesses, constitute this section of the report.

Table of Content: Global Itaconic Acid Market

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Itaconic Acid Market Landscape

Part 04: Global Itaconic Acid Market Sizing

Part 05: Global Itaconic Acid Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-itaconic-acid-market

Key Regions and Countries Studied in this report:

North America (The US, Canada, and Mexico)

Europe (Germany, France, the UK, and Rest of the World)

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America.)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

The research provides answers to the following key questions:

The 2020 Annual Itaconic Acid Market offers:

100+ charts exploring and analysing the Itaconic Acid Market from critical angles including retail forecasts, consumer demand, production and more

10+ profiles of top Itaconic Acid Market producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Any Questions? Inquire Here Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-itaconic-acid-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email corporatesales@databridgemarketresearch.com

View original post here:
Itaconic Acid Market Will Create New Growth Outlook In The Next Coming Years | Itaconix Corporation, Alpha Chemika, Thermo Fisher Scientific., Merck...

Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies – DocWire News

This article was originally published here

JNCI Cancer Spectr. 2020 Sep 11;4(6):pkaa081. doi: 10.1093/jncics/pkaa081. eCollection 2020 Dec.

ABSTRACT

BACKGROUND: Given similarities in the mediators of medication allergy (MA) and tissue response to radiotherapy, we assessed whether outcomes following prostate radiotherapy differ in patients with MAs.

METHODS: A total 587 men with known MA history and nonmetastatic prostate cancer underwent radiotherapy from 1989 to 2006. Clinicopathologic and treatment variables were analyzed for association with freedom from biochemical failure (FFBF) and late treatment-related, physician-defined Radiation Therapy Oncology Group gastrointestinal (GI) and genitourinary (GU) toxicity. Covariates identified on univariate analysis for toxicity and disease control were examined on multivariable analysis. All statistical tests were 2-sided, and a P less than .05 was considered statistically significant.

RESULTS: A total of 155 of 587 men (26.4%) had 1 or more MAs, most commonly to penicillin (n = 71), sulfa (n = 35), and aspirin or nonsteroidal antiinflammatory drugs (n = 28). On univariate analysis, men with MAs had superior 10-y FFBF (71.5% vs 63.5%, P = .02) and higher incidence of late GI grade 2 or higher (G2+; 20.6% vs 13.2%, P = .04) and grade 3 or higher (G3+; 7.5% vs 3.9%, P = .08) as well as late GU G2+ (42.5% vs 33.2%, P = .04) and G3+ (7.5% vs 3.0%, P = .02) toxicity than men without MAs. On multivariable analysis, MA history remained a statistically significant predictor of FFBF (hazard ratio [HR] = 0.64, 95% confidence interval [CI] = 0.43 to 0.93, P = .02), late G2+ GI (HR = 1.76, 95% CI = 1.06 to 2.90, P=.03), and G3+ GU (HR = 2.69, 95% CI = 1.16 to 6.27, P = .02) toxicity after controlling for corresponding covariates in each model.

CONCLUSIONS: Men with MAs had improved FFBF and increased treatment-related toxicity following radiotherapy for prostate cancer. MA history could be a relevant consideration in the management of men with localized prostate cancer.

PMID:33409456 | PMC:PMC7771007 | DOI:10.1093/jncics/pkaa081

View post:
Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies - DocWire News

Global Biochemical Reagents Market 2020 to 2025 Product, Distribution Channel, Region, Forecast and Opportunities during Ongoing COVID-19 Pandemic -…

A collective analysis report titled Global Biochemical Reagents Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 analyzes the market status and outlook from the view of players, countries, product types, and end industries. The report offers an exhaustive study based on current trends influencing this vertical throughout assorted geographies. The report provides a product overview and highlights of product and application segments of the market including price, revenue, sales growth rate, and market share by product. It presents comprehensive data that enhances the understanding, scope, and application of this global Biochemical Reagents report. The report also explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

More Trending Topics From Business Insights:

A comprehensive analysis of the competitive manufacturers, as well as the new entrants, is given along with their brief research. This report is specially designed to know accurate market insights and market status. The report studies the contestant performance of the global Biochemical Reagents market. Furthermore, the report encompasses details regarding the market share attained by these application segments along with their potential and consumption volume during the study period from 2015 to 2025. The market research report classifies the competitive spectrum of this industry in elaborate detail. Additionally, the major steps taken by key players to address the business challenges put forward are discussed in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/134181

Primitive vendors included in the market are: Beckton, Thermo Fisher Scientific, Abbott Laboratories, Dickinson & Company, Siemens Healthineers, Merck & Co., Inc, Roche Holding AG, Waters Corporation., Agilent Technologies, Inc, Bio-Rad Laboratories, Johnson & Johnson

The region-wise study of the global Biochemical Reagents market unfolds important regions like: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

In market segmentation by types, the report covers: , Polymerase chain reaction (PCR) reagent kits, Cell and tissue culture reagents, Electrophoresis reagents, Chromatography reagents, Others

In market segmentation by applications, the report covers the following uses: , Hospitals, Diagnostic centers, Academics and Research

Sales Forecast:

The report supplies historical revenue and volume that backing information about the market capacity, and it helps to evaluate numbers for key areas in the global Biochemical Reagents market. The study includes a share of each segment of the market combined with methodical information about types and applications of the market. This report delivers a forward-looking prospect of various factors driving or restraining market growth.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/134181/global-biochemical-reagents-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Reasons For Buying This Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global Biochemical Reagents Market 2020 to 2025 Product, Distribution Channel, Region, Forecast and Opportunities during Ongoing COVID-19 Pandemic -...

Scientists develop a cheaper method that might help create fuels from plants – The Ohio State University News

Scientists have figured out a cheaper, more efficient way to conduct a chemical reaction at the heart of many biological processes, which may lead to better ways to create biofuels from plants.

Scientists around the world have been trying for years to create biofuels and other bioproducts more cheaply; this study, published todayin the journal Scientific Reports, suggests that it is possible to do so.

The process of converting sugar to alcohol has to be very efficient if you want to have the end product be competitive with fossil fuels, said Venkat Gopalan, a senior author on the paper and professor of chemistry and biochemistry at The Ohio State University. The process of how to do that is well-established, but the cost makes it not competitive, even with significant government subsidies. This new development is likely to help lower the cost.

At the heart of their discovery: A less expensive and simpler method to create the helper molecules that allow carbon in cells to be turned into energy. Those helper molecules (which chemists call cofactors) are nicotinamide adenine dinucleotide (NADH) and its derivative (NADPH). These cofactors in their reduced forms have long been known to be a key part of turning sugar from plants into butanol or ethanol for fuels. Both cofactors also play an important role in slowing the metabolism of cancer cells and have been a target of treatment for some cancers.

But NADH and NADPH are expensive.

If you can cut the production cost in half, that would make biofuels a very attractive additive to make flex fuels with gasoline, said Vish Subramaniam, a senior author on the paper and recently retired professor of engineering at Ohio State. Butanol is often not used as an additive because its not cheap. But if you could make it cheaply, suddenly the calculus would change. You could cut the cost of butanol in half, because the cost is tied up in the use of this cofactor.

To create these reduced cofactors in the lab, the researchers built an electrode by layering nickel and copper, two inexpensive elements. That electrode allowed them to recreate NADH and NADPH from their corresponding oxidized forms. In the lab, the researchers were able to use NADPH as a cofactor in producing an alcohol from another molecule, a test they did intentionally to show that the electrode they built could help convert biomass plant cells to biofuels. This work was performed by Jonathan Kadowaki and Travis Jones, two mechanical and aerospace engineering graduate students in the Subramaniam lab, and Anindita Sengupta, a postdoctoral researcher in the Gopalan lab.

But because NADH and NADPH are at the heart of so many energy conversion processes inside cells, this discovery could aid other synthetic applications.

Subramaniams previous work showed that electromagnetic fields can slow the spread of some breast cancers. He retired from Ohio State on Dec. 31.

This finding is connected, he said: It might be possible for scientists to more easily and affordably control the flow of electrons in some cancer cells, potentially slowing their growth and ability to metastasize.

Subramaniam also has spent much of his later scientific career exploring if scientists could create a synthetic plant, something that would use the energy of the sun to convert carbon dioxide into oxygen. On a large enough scale, he thought, such a creation could potentially reduce the amount of carbon dioxide in the atmosphere and help address climate change.

Ive always been interested in that question of, Can we make a synthetic plant? Can we make something that can solve this global warming problem with carbon dioxide? Subramaniam said. If its impractical to do it with plants because we keep destroying them via deforestation, are there other inorganic ways of doing this?

This discovery could be a step toward that goal: Plants use NADPH to turn carbon dioxide into sugars, which eventually become oxygen through photosynthesis. Making NADPH more accessible and more affordable could make it possible to produce an artificial photosynthesis reaction.

But its most likely and most immediate application is for biofuels.

That the researchers came together for this scientific inquiry was rare: Biochemists and engineers dont often conduct joint laboratory research.

Gopalan and Subramaniam met at a brainstorming session hosted by Ohio States Center for Applied Plant Sciences (CAPS), where they were told to think about big sky ideas that might help solve some of societys biggest problems. Subramaniam told Gopalan about his work with electrodes and cells, and the next thing we knew, we were discussing this project, Gopalan said. We certainly would not have talked to each other if it were not for the CAPS workshop.

See original here:
Scientists develop a cheaper method that might help create fuels from plants - The Ohio State University News

Birds Have a Mysterious ‘Quantum Sense’. For The First Time, Scientists Saw It in Action – ScienceAlert

Seeing our world through the eyes of a migratory bird would be a rather spooky experience. Something about their visual system allows them to 'see' our planet's magnetic field, a clever trick of quantum physics, and biochemistry that helps them navigate vast distances.

Now, for the first time ever, scientists from the University of Tokyo have directly observed a key reaction hypothesised to be behind birds', and many other creatures', talents for sensing the direction of the planet's poles.

Importantly, this is evidence of quantum physics directly affecting a biochemical reaction in a cell something we've long hypothesised but haven't seen in action before.

Using a tailor-made microscope sensitive to faint flashes of light, the team watched a culture of human cells containing a special light-sensitive material respond dynamically to changes in a magnetic field.

A cell's fluorescence dimming as a magnetic field passes over it. (Ikeya and Woodward, CC BY 4.0)

The change the researchers observed in the lab match just what would be expected if a quirky quantum effect was responsible for the illuminating reaction.

"We've not modified or added anything to these cells,"saysbiophysicist Jonathan Woodward.

"We think we have extremely strong evidence that we've observed a purely quantum mechanical process affecting chemical activity at the cellular level."

So how are cells, particularly human cells, capable of responding to magnetic fields?

While there are several hypotheses out there, many researchers think the ability is due to a unique quantum reaction involving photoreceptors called cryptochromes.

Cyrptochromes are found in the cells of many species and are involved in regulating circadian rhythms. In species of migratory birds, dogs, and other species, they're linked to the mysterious ability to sense magnetic fields.

In fact, while most of us can't see magnetic fields, our own cells definitelycontain cryptochromes.And there's evidence that even though it's not conscious, humans are actually still capable of detecting Earth's magnetism.

To see the reaction within cyrptochromes in action, the researchers bathed a culture of human cells containing cryptochromes in blue light caused them to fluoresce weakly. As they glowed, the team swept magnetic fields of various frequencies repeatedly over the cells.

They found that each time the magnetic field passed over the cells, their fluorescent dipped around 3.5 percent enough to show a direct reaction.

So how can a magnetic field affect a photoreceptor?

It all comes down to something called spin an innate property of electrons.

We already know that spin is significantly affected by magnetic fields. Arrange electrons in the right way around an atom, and collect enough of them together in one place, and the resulting mass of material can be made to move using nothing more than a weak magnetic field like the one that surrounds our planet.

This is all well and good if you want to make a needle for a navigational compass. But with no obvious signs of magnetically-sensitive chunks of material inside pigeon skulls, physicists have had to think smaller.

In 1975, a Max Planck Institute researcher named Klaus Schulten developed a theory on how magnetic fields could influence chemical reactions.

It involved something called a radical pair.

A garden-variety radical is an electron in the outer shell of an atom that isn't partnered with a second electron.

Sometimes these bachelor electrons can adopt a wingman in another atom to form a radical pair. The two stay unpaired but thanks to a shared history are considered entangled, which in quantum terms means their spins will eerily correspond no matter how far apart they are.

Since this correlation can't be explained by ongoing physical connections, it's purely a quantum activity, something even Albert Einstein considered 'spooky'.

In the hustle-bustle of a living cell, their entanglement will be fleeting. But even these briefly correlating spins should last just long enough to make a subtle difference in the way their respective parent atoms behave.

In this experiment, as the magnetic field passed over the cells, the corresponding dip in fluorescence suggests that the generation of radical pairs had been affected.

An interesting consequence of the research could be in how even weak magnetic fields could indirectly affect other biological processes. While evidence of magnetism affecting human health is weak, similar experiments as this could prove to be another avenue for investigation.

"The joyous thing about this research is to see that the relationship between the spins of two individual electrons can have a major effect on biology," says Woodward.

Of course, birds aren't the only animal to rely on our magnetosphere for direction. Species of fish, worms, insects, and even some mammals have a knack for it. We humans might even be cognitively affected by Earth's faint magnetic field.

Evolution of this ability could have delivered a number of vastlydifferent actionsbased on different physics.

Having evidence that at least one of them connects the weirdness of the quantum world with the behaviour of a living thing is enough to force us to wonder what other bits of biology arise from the spooky depths of fundamental physics.

This research was published in PNAS.

Continue reading here:
Birds Have a Mysterious 'Quantum Sense'. For The First Time, Scientists Saw It in Action - ScienceAlert

Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of (68)Ga-PSMA-11 PET/CT in the biochemical recurrence…

This article was originally published here

Eur J Nucl Med Mol Imaging. 2021 Jan 8. doi: 10.1007/s00259-020-05086-1. Online ahead of print.

ABSTRACT

INTRODUCTION: Despite growing evidence of a superior diagnostic performance of 68Ga-PSMA-11 over 18F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11.

PATIENTS AND METHODS: Six centres performed 68Ga-PSMA-11 PET/CTs during the first 3 years of its use in France. Prior to each PET/CT, the patients data were submitted prospectively for authorisation to ANSM, the French Medicine Agency. The on-site readings of 1084 PSMA-11 PET/CTs in BCR patients whose recent FCH PET/CTs resulted negative or equivocal were pooled and analysed.

RESULTS: (1) The overall PR was 68%; for a median serum PSA level (sPSA) of 1.7 ng/mL, an oligometastatic pattern (1-3 foci) was observed in 31% of the cases overall; (2) PR was significantly related to sPSA (from 41% if < 0.2 ng/mL to 81% if 2 ng/mL), to patients age, to initial therapy (64% if prostatectomy vs. 85% without prostatectomy due to frequent foci in the prostate fossa), to whether FCH PET/CT was negative or equivocal (PR = 62% vs. 82%), and to previous BCR (PR = 63% for 1st BCR vs. 72% in case of previous BCR); (3) no significant difference in PR was found according to the imaging protocol: injected activity, administration of a contrast agent and/or of furosemide, dose length product, one single or multiple time points of image acquisition; (4) no adverse event was reported after PSMA-11 injection, even associated with a contrast agent and/or furosemide.

CONCLUSION: Compared with the performance of PSMA-11 PET/CT in BCR reported independently of FCH PET/CT in 6 large published series (n > 200), the selection based on FCH PET/CT resulted in no difference of PSMA-11 PR for sPSA < 1 ng/mL but in a slightly lower PR for sPSA 1 ng/mL, probably because FCH performs rather well at this sPSA and very occult BCR was over-represented in our cohort. An oligometastatic pattern paving the way to targeted therapy was observed in one fourth to one third of the cases, according to the clinico-biochemical context of the BCR. Systematic dual or triple acquisition time points or administration of a contrast agent and/or furosemide did not bring a significant added value for PSMA-11 PET/CT positivity and should be decided on individual bases.

PMID:33416958 | DOI:10.1007/s00259-020-05086-1

See the rest here:
Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of (68)Ga-PSMA-11 PET/CT in the biochemical recurrence...

John Friend obituary – The Guardian

My former colleague John Friend, who has died aged 89, was a biochemist at Hull University, where he was head of the plant biology department from 1969 until his retirement some 30 years later. He was also a keen advocate for Judaism in the Hull area, encouraging local people to gain a better understanding of the religion into which he was born and committed to promoting interfaith understanding.

John was born in Liverpool to Richard Friend, a draper, and his wife, Lilian (nee Jonas). At Liverpool Collegiate school he gained his A-level equivalents when only 16, so had to wait two years before attending Liverpool University, where he achieved a first in biochemistry, followed by a PhD.

He then moved to Cambridge University to study the effects of low temperatures on plant pigments that contribute to photosynthesis and which give many fruits and vegetables their distinctive colours. This work, important for food transport and storage, gained John another PhD.

I met him when he was appointed as a lecturer in botany at the University of Hull in 1960: I attended his first lecture there as a new undergraduate. John soon became a senior lecturer and then, in 1969, professor and head of the botany (later renamed plant biology) department. At Hull he continued his earlier research, together with new studies of how crop plants resist infection by pathogens, and his wider activities included becoming a signatory to the 1972 Blueprint for Survival, an early environmental manifesto. He also served as dean of science, then pro vice-chancellor (science) of the university.

Visits to other biochemists around the globe took him to the Hebrew University of Jerusalem, leading to a renewed interest in the teachings of Judaism. Being liberal-minded and not uncritical of Israeli politics, John believed in tolerance and the need to foster intercultural understanding through collaboration. He therefore became the first chair of the Hull Academic Study Group on Israel and the Middle East, organising academic exchange visits.

After he retired, John became active in the Hull and East Riding Interfaith group, welcoming schoolchildren and students to the Hull Reform Synagogue and patiently answering questions with his characteristic quiet enthusiasm. He also chaired the local Standing Advisory Council for Religious Education.

John was a gentle, cultured and compassionate man with an infectious sense of humour and an acute appreciation of lifes absurdities. He was a generous friend to many, and a dedicated family man.

He is survived by his wife, Carol (nee Loofe), a former student counsellor at the University of Hull, whom he married in 1956, and their three children, Mark, Jenny and Richard.

Visit link:
John Friend obituary - The Guardian

Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event – Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13th Annual Biotech Showcase Digital Event, January 11-15, 2021. Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, ITI-1000-A Novel Immunotherapy for GBM. Dr. Hearl will discuss ITIs investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITIs technology platform has the potential to utilize the bodys natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

Presentation details are as follows:

Who: William Hearl, Ph.D., Founder and CEO of Immunomic Therapeutics

What: ITI-1000--A Novel Immunotherapy for GBM

About UNITE

ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing target antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, neoantigens and producing antigen-derived antibodies as biologics. In early 2020, an investment of over $60M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. The Company has built a large pipeline from UNITE with four oncology programs, multiple animal health programs and a SARS-CoV-2 program to prevent and treat COVID-19. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.

Excerpt from:
Immunomic Therapeutics' CEO to present at the 13th Annual Biotech Showcase Digital Event - Business Wire

Nanomedic Technologies Appoints John R. Harper, PhD, to Board of Directors – BioSpace

LOD, Israel, Jan. 6, 2021 /PRNewswire/ -- Nanomedic Technologies,a leader in Electrospun Healing Fiber (EHF) technology for wound healing and skin regeneration, today announced the appointment of John R. Harper, PhD, a globally renowned expert in extracellular matrix biochemistry, regenerative medicine, and wound healing, to the company's Board of Directors.

"I am pleased to join Nanomedic's Board of Directors at such an exciting time in the company's development as it continues to expand availability of its advanced wound care technology to wider healthcare markets," said Dr. Harper. "Nanomedic's pioneering Spincare solution has the potential to dramatically change the process of wound care treatment as we know it. I look forward to bringing my experience of regenerative medicine to Nanomedic to help push forward important and long-awaited changes in wound care."

With more than 35 years' of experience, Dr. Harper currently serves as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care, where he is responsible for early-stage discovery and innovation related to advanced wound care. Dr. Harper previously served as Chief Technology Officer for 3M affiliate KCI, where he was responsible for innovation and technology development at the company's Center for Advanced Research and Technology. He also served as Vice President of Clinical Development and Clinical Sciences at biotechnology company LifeCell Corporation. Dr. Harper earned his PhD in Biochemistry from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center.

"We are honored to welcome Dr. Harper to Nanomedic's Board of Directors," said Dr. Chen Barak, Chief Executive Officer of Nanomedic. "His expertise and global recognition in regenerative medicine and wound care will prove invaluable for Nanomedic and our commitment to radically change the paradigm of wound treatment to allow patients to heal faster with less impediment to their daily lives."

Nanomedic's flagship product, the Spincare Wound Care System, is the first and only CE-cleared commercialized portable electrospinning wound treatment device on the market. The hand-held Spincare system utilizes proprietary Electrospun Healing Fiber (EHF) technology to enable faster and pain-reduced healing through site-specific real time printing of a nanofibrous matrix directly on to a wound that bio-mimics the structure of the human extracellular matrix. The unique structure of the matrix can treat even the most severe and complicated wounds with just one application.

"Dr. Harper brings vast knowledge in our industry and globalstrategic experience to our Board of Directors, an important step forward as we expand access of our Spincare System throughout Europe and prepare to enter the U.S. market," said Chen Katz, Active Chairman of Nanomedic's Board of Directors. "Our unique technology provides an exciting personalized total therapy solution for wound healing and we look forward to introducing our Spincare System to many more healthcare facilities worldwide."

About Nanomedic

Nanomedic Technologies Ltd. is a medical therapeutics company focused on transforming wound care both within and outside of hospital settings. Specializing in research, development and distribution of its proprietary Electrospun Healing Fiber (EHF) technology, Nanomedic is advancing the standard of care and helping improve wound care across the healthcare continuum. Nanomedic'sflagship product, the Spincare System, is the first and only CE-cleared commercialized portable electrospinning wound treatment device on the market. Founded in 2018, Nanomedic Technologies Ltd. is headquartered in Lod, Israel.For more information, visit https://nanomedic.com/Follow Nanomedic on LinkedIn: Nanomedic Technologies

Media Contact:Ellie HansonFinn PartnersEllie.Hanson@finnpartners.com+972-54-467-6980

Nanomedic ContactGary Sagivgary@nanomedic.com+972 54 562 7083

View original content:http://www.prnewswire.com/news-releases/nanomedic-technologies-appoints-john-r-harper-phd-to-board-of-directors-301201953.html

SOURCE Nanomedic Technologies

See original here:
Nanomedic Technologies Appoints John R. Harper, PhD, to Board of Directors - BioSpace

Shoe giveaway is good for the sole in Youngstown – Youngstown Vindicator

YOUNGSTOWN By merely being in the right place at the right time, Lisa Johnson found herself as a recipient of a 100-percent off sale.

Most of the time, I spend $50 or $60 for shoes for her, Johnson, of Youngstown, said about buying shoes for her granddaughter, Destiny Johnson, 4.

Johnson might as well have kept her money at home this time, however, because as she was driving on Belmont Avenue, a young woman holding a sign that mentioned a shoe giveaway caught her eye. A short time later, Johnson was being handed a free pair of size 12 Geer brand shoes, courtesy of the third annual giveaway event Friday afternoon at Union Baptist Church, 528 Lincoln Ave.

Hosting the one-hour outdoor driveup event was Relaced330, a Liberty boutique shop that opened late last year and specializes in restoring numerous brands of tennis and dress shoes, as well as purses, hats and designer bags.

In early 2015, Maeson Green, Relaced330s owner, developed an interest in and became talented at repairing his own shoes to always look new. Soon after, he began his own business called MBG Restoring, which has repaired and restored more than 1,500 pairs of tennis shoes, boots and dress shoes, according to its website.

In February 2020, MBG Restoring announced its decision to expand to Relaced330, the website states.

We make shoes look brand new, Green said Friday.

He and a team of five volunteers, most of whom are fellow Austintown Fitch High School graduates, were on hand to give away 150 pairs of new and restored shoes of all sizes for those age 1 to 18, as part of their effort to also give back to the community, he explained.

People need help, and this is just the avenue for you to get some help and go on about your day, Green said.

The merchandise included pairs of popular and special brand names such as Nike, Reebok, Puma, Skechers, Rock & Republic, Stacy Adams, Dockers, Totes, Catapult, Sonoma and Fila, along with special ones named after singer Marc Anthony and basketball legend LeBron James. Also on one of two long tables were pairs of Crocs.

Among those happy to assist with the effort was Lainie Simons of Austintown, an Ohio State University sophomore majoring in biochemistry.

Ive known Maeson since elementary school, and hes always been trying to do whats right, and Youngstown is struggling a bit, Simons said in explaining her main desire to be part of the giveaway.

A highlight of her experience was giving a 5- or 6-year-old girl in a vehicle a free pair of Adidas tennis shoes, Simons added.

Green and his team of volunteers also were happily surprised when Sydney Hull of Boardman pulled into the church parking lot.

I had them in the back seat and saw the sign and decided to donate, Hull said about having dropped off a pair of size 7 Nike Free Running shoes she had owned.

Green recalled that during the first event he hosted, only about 25 pairs of shoes were given away.

news@tribtoday.com

Today's breaking news and more in your inbox

Originally posted here:
Shoe giveaway is good for the sole in Youngstown - Youngstown Vindicator

L-Citrulline Market Overview | Key Vendor Landscape, Demand By Countries And Future Growth | Nutra Green Biotechnology Co.Ltd, MH2 BIOCHEMICAL, Alfa…

L-Citrulline Market Report acts as a valued source of information with which businesses can achieve a telescopic view of the current market trends, consumers demands and preferences, market situations, opportunities and market status. It helps businesses obtain granular level clarity on current business trends and expected future developments. The principal areas of market analysis such as market definition, market segmentation, competitive analysis and research methodology are studied very vigilantly and precisely throughout the report. L-Citrulline market research report assists businesses with the intelligent decision making and better manage marketing of goods which ultimately leads to growth in the business.

Market Overview:

Global L-Citrulline Market is expected to rise from its initial estimated value of USD 29.64 billion in 2018 to an estimated value of USD 48.14 billion by 2026, registering a CAGR of 6.25% in the forecast period of 2019-2026. This rise in market value can be attributed to the increase in awareness regarding the benefits of l-citrulline and rising levels of adoption of the product.

This L-Citrulline report provides overview of the market where it identifies industry trends, determines brand awareness and influence, provides industry insights and offers competitive intelligence. L-Citrulline Market report includes noteworthy information alongside future conjecture and point by point market scanning on a worldwide, regional and local level for the industry.

Download Free Sample Report with Statistical info @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-l-citrulline-market

Competitors Analysis:

Few of the major competitors currently working in l-citrulline market are KYOWA HAKKO BIO CO.LTD., Merck KGaA, TCI Chemicals (India) Pvt. Ltd., Newseed Chemical Co. Limited, Nutra Green Biotechnology Co.Ltd., MH2 BIOCHEMICAL, Alfa Aesar, abcr GmbH, SERVA Electrophoresis GmbH, DingKang Pharmaceuticals Ltd, and CJ CheilJedang Corp.

Scope of the Report:

Key Market Development:

The report provides in-depth information about profitable showing markets and analyzes the markets for the global L-Citrulline market. It provides full information about new product launches, current developments, and investments in the global market. The report delivers an complete evaluation of market shares, strategies, products, and manufacturing capabilities of the top players in the global market.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team who will ensure that you get a report that suits your needs.

For Any Enquiry or Specific Requirement Speak to Our Analyst @

https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-l-citrulline-market

L-Citrulline Market report covers the different market scenarios that have direct impact on the growth of the market. The report is structured with the meticulous efforts of an innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. In the end, the report makes some important proposal of the new project of L-Citrulline industry before evaluating its feasibility.

Key Pointers in TOC of L-Citrulline Market Report:

Sections 1: Definition, Specifications and Classification of L-Citrulline, Applications of L-Citrulline, Market Segment by RegionsSections 2: Technical Data and Manufacturing Plants Analysis of L-Citrulline, Capacity and, R&D Status and Technology Source, Raw Materials Sources AnalysisSections 3: Market Analysis, Sales Examination, sales Value InvestigationSections 4: Regional Market Investigation that incorporates North America, Europe, Asia Pacific, Latin America, Middle East & Africa Market ExaminationSections 5: The L-Citrulline Segment Market Analysis (by Application) Major Manufacturers Analysis of L-CitrullineSections 6: Market Trend Analysis, Regional Market Trend, Market Trend by Product TypeSections 7: Regional Promoting Type Investigation, Inventory network InvestigationSections 8: The Customers Examination of global L-CitrullineSections 9: L-Citrulline Research Findings and Conclusion, Appendix, system and information sourceSections 10: L-Citrulline deals channel, wholesalers, merchants, traders, Exploration Discoveries and End, appendix and data source.Continued..

Get Full Table of Contents with Charts, Figures & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-l-citrulline-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

Tel: +18883872818

corporatesales@databridgemarketresearch.com

See more here:
L-Citrulline Market Overview | Key Vendor Landscape, Demand By Countries And Future Growth | Nutra Green Biotechnology Co.Ltd, MH2 BIOCHEMICAL, Alfa...

Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution – The Hub at Johns Hopkins

ByHub staff report

Philanthropist and Johns Hopkins Medicine trustee David M. Rubenstein has made a $15 million commitment to the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins to support the department's research.

Image caption: David M. Rubenstein

The gift, his second pledge of that size to the department, will establish the David M. Rubenstein Precision Medicine Center of Excellence and will deepen his support for basic science researchers focused on the development of therapeutic approaches to preserve and restore hearing. Three strategic project teams, working in collaboration with researchers across Johns Hopkins University, will explore inner ear hair cell repair, sensory neuron repair, and nanomedicine drugs and drug delivery.

Rubenstein's gift will also support core facilities for these teams, consisting of:

Additionally, funds from this gift will support an annual conference and a speaker series.

"David's initial gift has helped Johns Hopkins researchers make important discoveries in several crucial areas related to hearing and hearing loss," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "But there is so much more to be done in this area, and once again, David has stepped forward. We are grateful for all that his generosity has made possible so far, and we are even more excited about what this new commitment will allow us to accomplish going forward. In the end, this work will help the millions of people who struggle every day with hearing problems."

Rubenstein's earlier gift to the department, made in 2015, funded the creation of an endowment to support cross-institutional accelerator grants. Any researcher at Johns Hopkins may apply for a grant for new or existing research to further the understanding of hearing. Grant amounts vary. In FY19, a total of $800,000 was awarded to seven different research projects, plus research core support. The earlier gift also established an endowed professorship, providing critical funds in perpetuity to support a leading faculty member in research and teaching.

"David's support has enabled innovative research projects that leverage the expertise and imagination of scientists, engineers, and clinicians from across Johns Hopkins," said Paul Fuchs, the inaugural David M. Rubenstein Research Professor of OtolaryngologyHead and Neck Surgery. "This is particularly important as we move from basic discovery of molecular and cellular mechanisms, to targeting these for therapeutic benefit. Current efforts employ gene therapy to correct inherited deafness, to regenerate cochlear hair cells, or to enhance protection from acoustic trauma. Other strategies aim to re-establish lost connections from inner ear to brain, a significant contributor to noise-induced and age-related hearing loss."

To learn more about some of the advances made possible through Rubenstein's generosity and hear from the researchers, visit the Otolaryngology-Head and Neck Surgery YouTube playlist.

Rubenstein is a founder and co-executive chairman of The Carlyle Group, a global investment firm. Rubenstein is a noted philanthropist and a long-time member of the Johns Hopkins Medicine board of trustees.

"It is a privilege to support the talented and committed researchers and doctors of Johns Hopkins who are helping people suffering from hearing loss," Rubenstein said. "I am impressed with the progress made in recent years and hope this new gift will accelerate and deepen those efforts."

Read more:
Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution - The Hub at Johns Hopkins

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – LionLowdown

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

https://lionlowdown.com/

Go here to see the original:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - LionLowdown

The Work of Architecture in the Age of Mechanical Reproduction – ArchDaily

The Work of Architecture in the Age of Mechanical Reproduction

Facebook

Twitter

Pinterest

Whatsapp

Mail

Or

This article was originally published on Common Edge.

I attended graduate school, in geography, in Tucson, Arizona, United States, in the late 1990s. Tucson draws fame from a number of things, including its Mexican-American heritage, its chimichangas, its sky islands, and its abundant population of saguaro cacti.

Plenty of things about Tucson, though, are perfectly, achingly ordinary. Perhaps the most ordinary thing about Tucson led me to develop something halfway between a hobby and an academic pursuit. On occasion, whether for sport or research, friends and I used to go sprawl-watching. We were not exactly, say, Walter Benjamin strolling through the arcades, embracing the human pageantry of Paris. But we did our best to plumb Tucsons depths.

Needless to say, sprawl-watching is not an action sport. It does not happen before ones eyes the way trains pass (for trainspotters, to cite another essential 90s reference) or planes land. And yet, there it was, bright as day, churning ever so slowly across the priceless desert habitat.

I grew up in a place that had once engaged in the action of sprawling but had solidified long before I came along. West Los Angeles of the 1970s and 1980s was, if not urban, at least built-out. But in the tract housing developments on Tucsons outskirts, or whatever the outskirts were at the time, sprawl was indeed a verb.

Naturally, you dont gobble up desert by the acre with anything resembling original architecture. The offenses of tract-home design have been cataloged prodigiously, and I wont belabor them here. Ill simply say that the uniformity dazzled me. A half-century after the heyday of Levittown, the business model was thriving.

If you spend any time around saguaro cacti, before long you cant help but marvel at the conditions that enable a tiny seed to take root, bubble up into a pup, and climb slowly skyward. The process requires just the right conditions, and it yields mighty succulents that are each mighty in their own way. Like snowflakes and fingerprints, no two are alike.

We cannot say the same for their neighbors, the tract homes, with their identical floorplans, identical facades, and identical amenities.

As modernity advanced, mass-produced housing arrived relatively late. The British manufactured ceramics and textiles by the late 1700s. Carnegies furnaces were on full blast by the early 1900s, and Ford developed the assembly line soon thereafter. During World War II, Douglas and Lockheed produced fighter planes by the tens of thousands. Craftsmanship and artisanal skill had been on the wane for a long time. In fact, by 1936, not much was unique anymore.

Thats the year Walter Benjamin published The Work of Art in the Age of Mechanical Reproduction. I prefer the more literal translation of its title: The Work of Art in the Age of Its Mechanical Reproducibility, implying that art does not merely accompany mechanical reproduction but it is, in many ways, superseded and changed by mechanical reproduction. Benjamin argued that art which is supposedly the apotheosis of uniqueness, originality, and human imaginativenesswas not merely a bystander in the industrial revolution, as the common title implies, but was, or could be, itself a product of technological production.

Even in the 1930s, it wasnt hard to imagine that the same mechanical processes that were producing cars and phones and chemicals could be trained to produce art as well. Or, rather, reproduce it. Benjamin does not discount the importance of the artist in the creation of original work. But he implies that human mastery of chemistry and materials science, paired with the precision of the assembly line, could essentially produce copies indistinguishable from their originals and do so in limitless numbers.

Mechanical arms could create brushstrokes in oil to mimic those of Da Vinci and Van Gogh, while mechanical chisels would turn fresh blocks of marble into new Davids and Birds in Space. They would not be forgeries but rather true reproductions. Originals would retain their importance only through their aurasthat ineffable contact with their respective creators, however arbitrary and immaterial that connection may be.

Benjamin probably overstepped. Even today, the originality of artworkits imperfectnessprovides one of our few steadfast links to our own humanity, even as technology eclipses anything Benjamin could have imagined. And yet, his thesis remains haunting, nihilistic, even: what if the mechanical can obliterate the artistic?

This question vexed me from the moment I read Benjamin as an undergraduate all the way up to the moment I visited my first Tucson tract home development. There, in the most unassuming, offensive landscape, I discovered that architecture may yet preserve our sense of humanity.

What struck me then as I strolled those expectant streets (possibly in ways that the residents never will) was that, for all the sameness of the homes, each one retained an essential uniqueness. Those developments, like most such developments, offered a few designs, each with lame, disembodied names like The Nantucket or whatever. They werent so many designs as they were collections of amenities and necessities united under roofs. And yet, each occupied its own special, if not necessarily distinctive, plot of desert.

Sure, machines can reproduce structures. But architecture is more than just structures. The one and only thing that we cannot reproduce, be it in a chugging factory a humming 3D printer, or a laboratory staffed by autodidactic nanobots, is landscape. I say landscape deliberately. We can absolutely produce and reproduce land. Many cities sit on landfill of some sort, from the Battery to the Bay Bay to Murano Island and The Palm Jumeirah. But, what every piece of land can claimwhether created by man or plate tectonicsis its uniqueness. We have one Earth, and every piece of it differs from every other piece. The totality of architecture encompasses structures, setting, relationships, uses, and even ideas that, in combination, create a landscape.

Lets consider obvious exemplars: the Golden Gate Bridge, the Sydney Opera House, the monasteries of Tibet, the five-star bungalows of Tahiti, the Houses of Parliament, the Getty Center, Notre Dame, and the Casa Malaparte, and, yes, the Guggenheim Bilbao. (Esoteric though they may be, lets also add works of land art, like Spiral Jetty and The Lightning Field.) A great many architectural masterpieces owe their acclaim not just to their designthe part that lives on paper and could be constructed almost anywhere, but from their relationship with the land. Each of these structures looks the way it does because of its site and situation; from inside, they each look upon different views and, therefore, are capable of inspiring their own unique versions of awe. Its in these landscapes where humanism, if not humanity itself, may make its last stand.

My own home is not a masterpiece because it enjoys a slightly different view and slightly different elevation from the one across the street. But the uniqueness of landscape ensures that architecture can be unique. And, just as Benjamins point about reproducibility was subtle yet powerful, so is the importance of landscape.

Benjamin was a weird one. On the one hand, he celebrated the extreme humanity of the city and the elemental activity of walking. On the other hand, he helped usher in not just the modern agecharacterized by mechanical productionbut indeed the postmodern age, characterized by reproduction and simulacrum. As intellectually interesting as postmodern ideas may be, they remain distressing. Nothing is special when everything is fake. Taken to its extreme, postmodernism presages the day when artificial intelligence does all our work for us and when no human relationship is unmediated by technology.

Thats why I take solace in special places and un-special places alike. And its why I put a degree of faith in architecture, even when so many other human endeavors have slid into banality and self-reference. Of course, not every architect can, or should, be another Utzon or Meier. The world will always need far more workaday structures than it does masterpieces. The more we must strain to see our auras amid the banality of postmodern life, the more we may need to tighten our grip on the incredible places humanity has created.

Nearly two decades later, I hope that plenty of happy families are living in those Nantuckets and Saratogas and whatevers. By now, many have raised children and perhaps sent them off to graduate school. They may or may not appreciate their unique places in the world. Indeed, placelessness is more prevalent than we ever could have imagined, with so much of life taking place online and in the cloud. But, while deserts sands may shift and buildings may topple, the fundamental facts of the land persist.

Go here to see the original:
The Work of Architecture in the Age of Mechanical Reproduction - ArchDaily

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans – Science Magazine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoonotic virusone that spilled over from another species to infect and transmit among humans. We know that humans can infect other animals with SARS-CoV-2, such as domestic cats and even tigers in zoos. Oude Munnink et al. used whole-genome sequencing to show that SARS-CoV-2 infections were rife among mink farms in the southeastern Netherlands, all of which are destined to be closed by March 2021 (see the Perspective by Zhou and Shi). Toward the end of June 2020, 68% of mink farm workers tested positive for the virus or had antibodies to SARS-CoV-2. These large clusters of infection were initiated by human COVID-19 cases with viruses that bear the D614G mutation. Sequencing has subsequently shown that mink-to-human transmission also occurred. More work must be done to understand whether there is a risk that mustelids may become a reservoir for SARS-CoV-2.

Science, this issue p. 172; see also p. 120

See the original post here:
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans - Science Magazine

Revenge is a dish best served with a side of kindness – Sentinel & Enterprise

Were all human. And humans are all, to one degree or another, vengeful. Even those of us who work so hard to overcome the lesser angels of our nature love a good car-keying breakup song or cant help dropping a snarky Yelp review when crossed.

Why do we feel the need for revenge? It doesnt seem to have an obvious biological value, yet thats the likely point of origin. Science demonstrates that vengeance activates the reward centers of our brain. So thats at least an indicator that biology is somehow involved in our desire for revenge.

But why? What purpose does revenge have for our biology? Why is it hardwired into our brains that we need to get back at someone for pissing us off? Clearly, its something we deem to be of great importance to our civilization that we curtail this natural desire through our laws and faith systems designed around a goal to sublimate the human instinct for revenge. Christianity is based almost entirely on this single idea alone: Love your enemy.

One study acknowledges that what the angry mind really wants is not so much the meting out of punishment or suffering, but to accomplish a change of heart in those who have trespassed against us. We want the other person to change, to acknowledge what they did, to understand how it made us feel, to promise never to do it again. Most of the time, thats a tall order. But thats what we want.

And theres a clue here about why we are intrinsically wired for revenge. The clue is in our desire to accomplish a change of heart in the one who acted against us.

Its true that revenge feels good. At least for a moment. Its the subject of nearly all television, film and books. We cheer when the villain gets their reward. It translates into our own lives and personal experiences where we think we will feel as good by committing our own vengeful acts as we did when seeing the villain get theirs. The irony is that revenge gives us only a short-term boost of positive brain chemicals followed by a long period of slow deterioration of that feeling. We eventually end up feeling worse than we did before. We end up re-injuring ourselves. The villain wins in the end to the same degree as our unwillingness to let our sense of vengeance go.

It turns out that there are deeply biological reasons for revenge. They hinge upon the fact that we are a communal species. Biologically, revenge is a social deterrent. Through our retributive actions, be they wise or not so much, we are attempting to cultivate behavioral change for the better within our tribes and social groups. When employed judiciously, revenge is actually meant to prevent negative actions taken upon us in the future. Its meant to deter predators or those who would encroach upon our territory and modify behavior among the members of a society. It is also a demonstration of prowess and strength, things that are of prime importance in reproduction of any species. Standing up for ourselves is attractive.

But knowing that standing up for ourselves can go too far because we are a greedy species our tendency toward gluttony will take the form of revenge if not careful. We can deteriorate into obsessively fixating on getting back at those who have hurt us. Hence, the formation of laws and life practices.

Having demonstrated that revenge is an inevitable reality for us all, how might we choose to handle it? Of course, theres plenty of advice out there. But how to choose from among them? When in doubt, always choose the most loving alternative.

I practice a form of revenge, whenever possible, that entertains me to no end. Kindness. It really drives an enemy crazy. They dont know what to make of it.

Years ago, I used to love to shovel my cranky neighbors sidewalk in the winter. He was so mean he even made a report once to the citys building department that I am gay. (As if that somehow would make a zoning impact upon the community?) He was a perfect candidate for a revenge of utter kindness. He really had it coming to him.

I dont think I ever enjoyed shoveling so much in my life as I did his sidewalk, watching from the corner of my eye as he peered out through the curtains. I would imagine him flummoxed and confused. He was far too old to shovel for himself, and as the laws require the sidewalks be cleared in front of everyones homes, he actually needed someone to do it. But he had no friends of which I was aware and certainly was too cheap to hire someone. I know he was a stickler for law and order. It probably rankled him that the sidewalk wasnt clear. He may even have worried about getting a citation. He needed me. Ha ha.

Its true that he may have been sitting inside thinking he was the one taking revenge upon me rather than the other way around. He may very well have thought that he was the winner of this little battle. But I know he was wrong. Im just as happy to entertain a thought that he was smugly satisfied, because the brain chemicals we both had were good ones, and Im the one who caused it.

In the final analysis, its up to us how we manipulate our desire for revenge within us. There are many things about our human nature we cannot change but for which we can create balance. The prime directive is to feel good. Not just in the short term, but also the long term. The main goal of life is joy, and anything that interferes with that is anathema. It will not rise to the top, for it is not natural to us.

Our biology may wish to enact measures to protect itself and its interests that is logical. But make careful note of this desire and take steps to ensure that what tastes good right now wont make you sick later. Revenge is a drug with harmful side effects. See to it that you make loving use of it. Surprising and positive changes will occur that you could not have imagined.

Congratulations in advance.

Wil Darcangelo, M.Div., is the minister at First Parish UU Church of Fitchburg and of First Church of Christ Unitarian in Lancaster. He is the producer of The UU Virtual Church of Fitchburg and Lancaster on YouTube and host of the Our Common Dharma podcast series. Email wildarcangelo@gmail.com. Follow him on Twitter @wildarcangelo. His blog, Hopeful Thinking, can be found at http://www.hopefulthinkingworld.blogspot.com.

See the article here:
Revenge is a dish best served with a side of kindness - Sentinel & Enterprise

Department of Health can’t give timeline for rollout of publicly-funded IVF – TheJournal.ie

A FURTHER WAIT is facing people who were hoping that publicly-funded IVF would be rolled out in the new year, as promised by the then Minister for Health Simon Harris last December.

Details of the model of care were announced by the Department last December with phase two seeing the introduction of tertiary infertility services, including IVF, in the public health system.

A spokesperson for the Department of Health told Noteworthy that it is not possible at this time to give a definitive timeline for the completion of phase two of the rollout of the model of care. They added that it is contingent on the [assisted human reproduction] AHR legislation being commenced, as well as the required resources being in place.

At the time of the announcement this time last year, Minister Harris told TheJournal.ie: I think its likely to take most of 2020 to pass and commence the legislation. So realistically I think youre looking at 2021, in terms of IVF being available through the public health service and being publicly funded.

A public fund which promised financial support for people undergoing fertility treatment was first announced in 2017.

Its really regrettable, said Professor Mary Wingfield, clinical director of the Merrion Fertility Clinic.

The model of care will be rolled out on a phased basis over the course of the coming years, according to Health Minister Stephen Donnellyin response to a parliamentary question from Fine Gael TD Neale Richmond on fertility funding.

Phase one involves the setting up of Regional Fertility Hubs and 2 million was provided for 2020 in order to commence the development of these, a Department spokesperson told Noteworthy.

Donnelly also said that the development of these hubs has slowed due to the management of the Covid-19 pandemic but additional funding is being made available in 2021 to facilitate the continuation and completion of phase one.

Minister for Health Stephen Donnelly Source: Sasko Lazarov via RollingNews.ie

Legislation link convenient

Wingfield said there has been a little bit of progress with funding provided to locations around the country to develop secondary level care. One of these will be set up in Holles Street and she said theyre hoping to set that up next year.

This covers investigations into why a couple might not be getting pregnant and surgery for a small group of women who arent ovulating, according to Wingfield. Its a step towards trying to have a more organised system which would then act as a referral system. However, she added that theres still no funding for IVF once referred.

That comes in phase two of the model of care. In the recent parliamentary question response Donnelly stated that this phase will not commence until such time as infertility services at secondary level have been developed across the country and the AHR legislation is commenced.

This link of the model of care to legislation is a convenient way of putting it off, according to Wingfield.

I dont see why the funding has to be linked to the legislation. I cant see any medical reason. People are allowed to have treatment if they can afford it so I dont think the legislation should be linked to it.

When asked about the need to link the model of care and legislation, a Department spokesperson said while the number of people accessing AHR treatments and services in Ireland is increasing, the provision of these services remains largely unregulated, which means that individuals are availing of often highly complex procedures in a legal vacuum.

They added that this legislation is required in order to assist people to have children safely, to clarify the legal position of children born from these practices, and to ensure research and new reproductive technologies are carried out within a prescribed ethical framework. It will also provide for the establishment of the AHR Regulatory Authority.

Decades of waiting for bills

The legislation has not yet gone through any of the necessary stages of the Seanad and Dil. Drafting has been ongoing for a number of years, with many iterations of human reproduction bills going through the Oireachtas unsuccessfully over the past 20 years.

Thecurrent draft billis on the Departments priority list for publication during the spring legislative term, said the spokesperson. They stated:

We understand the impact that the issues of infertility and subfertility can have at an individual level. A diagnosis of infertility can be a source of severe emotional and psychological distress, physical discomfort and financial hardship.

In a separate statement toNoteworthythe spokesperson also said that while AHR treatment is not currently funded by the Irish public health service, a defined list of fertility medicines needed for fertility treatment is covered under the High Tech Arrangements administered by the HSE in addition to tax relief on costs of AHR treatment.

Lack of public funding unjust

Lack of public funding for fertility treatment is socially unjust, according to Rory Tallon. Source: Rory Tallon

Around one in four couples in Ireland experience difficulty when trying to have children and many face thousands of euro in costs if they seek assisted human reproduction (AHR) treatment. This has led many people to travel overseas for cheaper fertility treatment something that the pandemic has impactedas reported recently byTheJournal.ie.

The cost of IVF is quoted as around 4,500 on the main Irish fertility clinic websites but this can quickly turn to tens of thousands when multiple cycles as well as other tests and treatments are needed, according to Rory Tallon, who underwent IVF with his wife Sarah.

Tallon has cystic fibrosis (CF) which causes infertility in about 98% of men due to the absence of the sperm canal the vas deferens. However, sperm can be extracted by clinicians and through IVF it is possible for men with cystic fibrosis to become fathers.

It was a comparable cost to a wedding or a house deposit, said Tallon who added that he was lucky his wife already had a house when they met so he could use the money he saved to help fund the treatment. The couple had to undergo a number of cycles of IVF before the birth of each of their two daughters.

Its unjust that because its so expensive it is practically only available to the middle and upper classes that can afford it. If youre a couple from a lower socioeconomic position, you just wouldnt be able to.

With new treatment, the health and quality of life of people with cystic fibrosis is improving year on year, but many adults work part-time or are not able to work due to health reasons, according to Tallon who is also employed as an advocate for CF Ireland. A survey conducted by the charity in 2017 found that 14% of respondents were too ill to work.

Unless youve been very prudent with your finances, you probably wont have a huge savings reservoir capable of meeting [the cost] of IVF.

CF Ireland gives 55,000 worth offertility grantsto around 20 people 80% men with cystic fibrosis every year from money raised through fundraising. This money covers a portion of the cost of fertility treatment.

The charity also gives a grant to cover part of the cost of preimplantation genetic diagnosis. Three cycles of this test are covered for couples who are carriers of a genetic disorder on the NHS but not in Ireland.

With infertility a growing issue in the general population, Tallon said this is not just a niche CF issue and there is a need for Government funding for infertility. Couples might think it will cost a few thousand but very quickly could find themselves on their third or fourth cycle, he explained.

Thats where it is difficult. Thats where the Government should really play a part.

People want answers

Another group that often requires fertility treatment are people who have undergone treatment for cancer. Paul Gordan, policy and public affairs manager of the Irish Cancer Society said that we dont want to see people who cant afford IVF not having access to a treatment that is available in most European countries.

Ireland is the only EU country not to offer state funding for assisted reproduction even though the World Health Organisation recognises infertility as a medical condition. Lithuania joined us up to recently but now their national compulsory health insurance reimburses providers for two cycles of IVF per couple treated.

Gordan said there has been some development in terms of regional hubs but we have seen a couple of missed timelines that have been set about when people will have access to publicly funded IVF. He added that IVF is what people really want to see as its really important for people with cancer and cancer survivors when they progress into a life [after treatment].

The fertility of both women and men can be impacted by both different types of cancer as well as cancer treatment. Some have the option of freezing their semen or eggs in order to preserve their fertility but may then need treatment such as IVF in order to have a baby.

Fertility preservation for people with cancer is currently provided by the State but to date was only offered to adults in one location the Rotunda Hospital.

Professor Mary Wingfield is calling on the implementation of publicly funded fertility treatment. Source: Prof Mary Wingfield

This is another area that needs to be looked at, according to Prof Mary Wingfield. There is some funding at the moment but it goes to one clinic and its inadequate.

A spokesperson for the HSE told Noteworthy that while this service was originally provided by the Rotunda, it subsequently was acquired by a private provider who continued to provide the service at the Rotunda. This private provider has since relocated and is no longer based there. They continued:

As the range of services that can potentially be offered in the area of fertility preservation is expanding it is now timely to review the service provision.

The Irish Cancer Society in conjunction with Merrion Fertility are funding a Childhood Cancer Fertility Project over the coming years in order to improve access to fertility preservation for children and young adults, according to Gordan. He hopes that a more sustainable funding line will be obtained once their project demonstrates its effectiveness.

We feel there should be a system where there is equity of access to fertility treatment. We want cancer patients to have the same opportunities as others to have children regardless of their background or income.

Gordon said there was an expectation that publicly funded IVF would become available sooner which has led to frustration for everyone as there is a timeline a clock on this for many people. He added there needs to be more urgency for the progression of both public funding and the passing of the AHR legislation.

It would be great to understand the timeline for both but in reality people want publicly funded fertility treatment and want answers as to when that will happen.

Funding Fertility Investigation

Has the delay in publicly funding IVF destroyed peoples chance to have children?

ThroughNoteworthy, we want to do an in-depth investigation intothe impact of the wait for public fertility funding andlook at the potential obstacles to overcome in order to put IVF through the public system.

We want to compare fertility costs in Ireland to other EU countries and look into the type of state funding offered. We also want to investigate the supports offered to people who need fertility-related procedures or treatments due to health complications or illness.

Heres how to help support this proposal>

Continued here:
Department of Health can't give timeline for rollout of publicly-funded IVF - TheJournal.ie

COVID-19 vaccine race: Where they stand currently – The Tribune India

New Delhi, January 9

Almost a year into the COVID-19 pandemic, about 200 vaccine candidates are in the works and 10 have been either approved by several countries or are under limited emergency use.

As India prepares to launch its vaccine drive on January 16, here is a look at the options:

COVAXIN

Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine was granted emergency use authorisation in clinical trial mode by the Indian government this week.

It is an inactivated vaccine developed by chemically treating novel coronavirus samples to make them incapable of reproduction. This process leaves the viral proteins, including the spike protein of the coronavirus which it uses to enter the human cells, intact.

Given as two doses, three weeks apart, the viral proteins in the vaccine activate the immune systemand prepare people for future infections with the actual infectious virus. According to Bharat Biotech, the therapeutic can be stored at room temperature for at least a week.

A study on thePhase trial published in the preprint server medRxiv in December showed thetherapeutic doesnt cause any serious side effects. However, there has been no further data released in the public domain which could demonstrate that the vaccine is safe and effective.

ICMR-Bharat Biotech vaccine is a killed whole-virus vaccine and there are absolutely no data available so far on its protective efficacy. I am critical of its getting approval by the authorities, immunologist Vineeta Bal, affiliated with the National Institute of Immunology in New Delhi, told PTI.

COVISHIELD

Co-developed bythe University of Oxford and British-Swedish company AstraZeneca and known as Covishield in India, the vaccine was the first on which a scientific study was published based on Phase 3 clinical trials.

It has so far been given emergency use authorisation in the UK, Argentina, Mexico and India.

Scientists have engineered a version of adenoviruses that infect chimpanzees to carry the gene responsible for the spike protein of the novel coronavirus.

It requires two doses, provided four weeks apart, to produce the desired effects.

Manufactured by the Serum Institute of India, Covishield will be sold at Rs 1,000 per dose in the private market but cost the Indian government only Rs 200, said SII CEO Adar Poonawalla.

Oxford-AstraZeneca-Serum Institute vaccine has shown protective efficacy in global trials to the tune of 60-70 per cent. While clear data from bridging trials in India are not available, the vaccine is certainly proven safe, Bal said.

According to virologist Upasana Ray from the CSIR-Indian Institute of Chemical Biology, Kolkata, the AstraZeneca-Oxford vaccine is less restricted in terms of cold storage as it can be stored, transported and handled at normal refrigerator temperatures (2-8 degrees Celsius) for at least six months.

MODERNA

The mRNA vaccine by US-based company Moderna has so far been approved for use in Israel, the EU, Canada and the US.

A studyof the efficacy of Moderna vaccine revealed it has 94.1 per cent efficacy in preventing the disease. In this type of vaccine, the messenger RNAor mRNAacts as a blueprint for the production of the coronavirus spike protein and is encapsulated by lipid molecules and delivered into human cells.

The cells of the vaccine recipient then use this mRNA genetic code to produce the viral protein to train the immune system for a future encounter with the infectious coronavirus. Administered as two doses, four weeks apart, the Moderna vaccine can reportedly be stored in the refrigerator at 2-8 degrees Celsius for up to 30 days. At -20 degrees Celsius it can be stored for up to six months. This is still a challenge for many developing countries in the tropical regions that experiencevery high temperatures in the summer months.

In November last year, Moderna Chief Executive Stephane Bancel told a German weekly that the companywould charge governments between USD 25 and 37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered.

PFIZER-BIONTECH

The US-backed Pfizer-Biontechs COVID-19 preventive, like the Moderna vaccine, is based on the segments of the genetic material of the novel coronavirus.Preliminary data from the clinical trials showed that two doses of the vaccine, given three weeks apart, provided an efficacy of over 90 per cent.

Following the results, the UK, Canada, the EU and Saudi Arabia have approved the Pfizer vaccine for use. Several countries, including the US, Singapore, Argentina and Mexico, have given emergency use authorisation.

One limitation for the Pfizervaccine has been its requirement for ultracold storageup to -70 degrees Celsius.

Each dose is reportedly priced at USD 37.

PUTNIK V

Sputnik V from RussiasGamaleya Research Institute has been approved for emergency use by several countries but awaits more results from Phase 3 trials.

An adenovirus vectored vaccine, Sputnik V is produced using a combination of two adenoviruses called Ad5 and Ad26.Preliminary evidence from Phase 3 trials indicates it is 90 per cent effective when given as two doses, three weeks apart.

In November, the Russian Direct Investment Fund said the cost of the vaccine would be less than USD 10 per dose starting from February 2021. It said the dry form of the vaccine can be stored at 2-8 degrees Celsius, and does not need freeze storage.

CONVIDECIA

The adenovirus vectored vaccine developed by the Chinese company CanSino Biologics is also under Phase 3 trials and has already been approved for limited use by the Chinese military.

Since August, the vaccine has been part of Phase 3 trials in several countries, including Russia, Mexico and Pakistan.

CORONAVAC

Another Chinese company, Sinopharm, has also made progress with itsinactivated vaccine dubbed CoronaVac. It has been given emergency approval for limited use in the country. The vaccine is reportedly provided as two doses, administered two weeks apart. Scientists are yet to publish a study on the trial conducted so far.

VECTOR INSTITUTE

Russias Vector Institute has developed a protein vaccine. It is currently under Phase 3 clinical trials. It uses modified versions of the coronavirus spike protein to induce immunity. The vaccine reportedly can be stored at 2-8 degrees celsius for up to two years. Data on the efficacy of the therapeutic is yet to be released.

NOVAVAX

After showing promising results in Phase 1-2 trials, and in animal experiments, the vaccine developed by US company Novavax is currently under Phase 3 clinical trials. It uses modified versions of the coronavirus spike protein to induce immunity, and can reportedly be stored at 2-8 degrees Celsius. After some setbacks in manufacturing the doses required for the Phase 3 study in the US, the trial was finally launched on December 28.

JOHNSON&JOHNSON

The adenovirus vectored vaccine by the American company has shown protection against the coronavirus in experiments in monkeys and is currently part of Phase 3 clinical trials. Unlike other vaccines, this vaccine is reportedly provided as a single dose, but trials are currently underway to test its efficacy as two doses. The company had noted that the therapeutic can be stored for up to three months when refrigerated at 2-8 degrees Celsius, and up to two years when frozen at -20 degrees Celsius. PTI

See more here:
COVID-19 vaccine race: Where they stand currently - The Tribune India

A good year for the Philippine eagle in 2020, but not for its supporters – Mongabay.com

MINDANAO, Philippines Efforts to conserve the critically endangered Philippine eagle, one of the rarest raptors in the world, soared high even amid the COVID-19 pandemic.

Despite the global havoc wreaked by the health crisis, the year 2020 ended on a high note for eagle conservationists, with at least two eagle families sighted in the Davao region of the southern Philippine island of Mindanao.

The Philippine eagle (Pithecopaga jefferyi) enjoys a special status as the national bird of the Southeast Asian nation, but faces extinction due to hunting and loss of habitat. Growing the population is difficult, as the birds are slow to reproduce. It takes them five to seven years to mature sexually, after which the female lays a single egg every two years.

There are only an estimated 400 nesting pairs of Philippine eagles left in the wild, so the sighting of new eagle families is always a milestone to celebrate for the Philippine Eagle Foundation (PEF), a nonprofit that has worked for more than 30 years in conserving the species.

Dennis Joseph Salvador, executive director of the PEF, said hes optimistic the protection of the Philippine eagle is off to a good start for 2021, given the achievements of 2020, which came despite the debilitating impacts of the COVID-19 pandemic and the threats the birds face daily from human activities such as hunting and illegal logging.

We have demonstrated over the past 30 years our commitment to conserve the mighty Philippine eagle and by hook or by crook, we will sustain that next year and in the years to come, he told Mongabay.

In addition to the sighting of new families, in the seven months that followed the March 2020 start of lockdown in the Philippines, the foundation rescued seven birds with the help of mobile technology and social media.

PEF credited this record number of rescues to heightened public awareness and involvement of local governments in eagle conservation, rather than to an uptick in the number of captured or injured birds.

Most of the rescued birds had been captured by trappers, with one sold for 8,000 pesos (around $170) by the trapper to an outdoors enthusiast.

In some instances, rescuers had to work in the dead of night and traverse rugged terrain to fetch the distressed eagles hundreds of kilometers away in remote mountain villages.

Of the seven Philippine eagles rescued since the start of the lockdown, one died due to malnutrition, three were released back to the wild, and three remained at the PEFs rehabilitation center.

We are very glad that despite the pandemics travel and movement restrictions, we were able to save six of these seven precious birds, with three of them healed and successfully released back to their respective forest homes, Salvador said.

The PEF says successful rescues involve collaborating with a wide variety of actors, including concerned citizens reporting eagles in distress; officials from the Department of Environment and Natural Resources (DENR) and local governments; as well as organizations that support the PEF. After each birds release, it continues to be monitored with the aid of community volunteers and their respective village and Indigenous community organizations.

One such release came on July 28, as the world celebrated World Nature Conservation Day. The rescued eagle, named Makilala Hiraya, was released back into the wild, tagged with a GPS/GSM tracker on her back, in the first such event ever livestreamed on Facebook.

But what astonished Philippine eagle conservationists last year were the sightings, a few weeks apart, of two families of the raptors: mated pairs and their offspring. The first family was spotted within Mount Apo Key Biodiversity Area (KBA) in November and the other in December within Mount Kampalili-Putting Bato KBA. Both KBAs are on the island of Mindanao.

Jayson Ibaez, research and conservation director at the PEF, said the organization has for years been searching for eagle nesting sites, particularly in Mindanao, where half of the estimated 400 nesting pairs of Philippine eagles are believed to live.

The recent sightings of two families of Philippine eagles indicate that the forests where theyre seen are still pristine and rich in prey items for the raptors such as macaques, flying lemurs, hornbills, palm civets and snakes, among others, he told Mongabay.

Unless disturbed or destroyed by human activities, Philippine eagle nest sites are considered ancient breeding grounds, since generations of eagle pairs will occupy the nest over and over again.

Conserving these core areas of reproduction and keeping the nesting pair and their young safe is pivotal to the success of saving the species from being lost forever, Ibaez said.

In November, the PEF team, in collaboration with state-run Energy Development Corporation, which runs a geothermal power plant within Mount Apo, launched the Search for the King of Birds campaign in the area.

The team spent 192 observation hours deep in the forest and emerged victorious after at least eight sightings of nesting pairs of Philippine eagles and their offspring.

Ron Taraya, senior biologist and expedition leader at the PEF, told of how he and the team got within 200-300 meters (660-980 feet) of a juvenile Philippine eagle in the wild. The bird exhibited characteristics typical of a 2-year-old of the species: awkward hunting moves, lower flight confidence, and limited flight duration.

It amused us watching the bird take on a group of long-tailed macaques foraging on an escarpment just in front of the waterfalls, Taraya said.

The young raptor failed to kill the target macaque, as the group faced off with the bird and grunted threateningly, prompting the eagle to back off and fly into a tree above the ledge.

A few days prior to the close encounter with the juvenile, the team saw a pair of eagles feeding their young one with freshly killed prey following the latters food begging calls. During the expedition, the team also documented the juveniles parents aerial rituals that appeared to be a courtship routine.

The two eagles mutually presented their talons in mid-air, called talon presentation,' Taraya said. They also did several bouts of flying together in spirals, or mutual soaring. Then they flew to different directions; one disappearing inside the deep gorge, while the other landed on an emergent tree. There, the eagle stayed on its perch cleaning its feathers with its beak, called preening. It was also seen scratching, stretching and moving its head. After performing these general maintenance behaviors, the eagle finally flew off and glided beyond the waterfalls until it disappeared behind the tree line.

In Mindanao, September to January is typically nesting season for Philippine eagles, and courtship displays precede each egg-laying event. Eagle pairs at several nest sites across Mindanao start their courtship rituals as early as July, and the routine can persist even after the pair has started rearing a chick.

The second sighting of a family of Philippine eagles, in early December, was in the town of Lupon, in the province of Davao Oriental, within Mount Kampalili-Puting Bato KBA. A team from the provincial government was assessing the areas potential tourism sites when it spotted the birds.

Images of the juvenile perched on a tree and two bigger eagles were captured by a government photographer, Eden Jhan Licayan, which the PEFs Ibaez later confirmed as being Philippine eagles.

Ibaez said a single eagle pair needs 4,000-11,000 hectares (10,000-27,000 acres) of forest to thrive and multiply.

While roughly 200 eagle pairs are believed to survive in Mindanao, Ibaez said only 39 pairs have actually been documented. This means more expeditions are needed to get the real numbers, he said.

We are very happy every time we discover new pairs, Ibaez said. It is important to locate the nesting sites so that we can put in place protective measures to ensure they will be out of harms way so that the species can reproduce and will not become extinct.

The oldest nesting site within Mount Apo was discovered in the 1970s, near its foot. An eagle pair continues to frequent the area today, according to Ibaez. The birds can live up to 40 years.

The wider Mount Apo range spans at least 90,000 hectares (222,000 acres), of which only two-thirds are classified as a protected area, adding extra complexity to the task of protecting eagle habitat and nesting sites.

To help with the conservation of the forest and the Philippine eagles in Mount Apo KBA, the Davao City government engages Indigenous communities through its Bantay Bukid (Forest Guard) initiative. Under the scheme, some 200 Indigenous men have been recruited as volunteer forest guards, for which they get a monthly allowance of 2,000 pesos (about $40), to patrol four identified nesting sites. Together, they keep watch over some 25,000 hectares (62,000 acres) of forest.

The Bantay Bukid program has significantly augmented the forest protection work force of the DENR in the area. From a ratio of one personnel for every 7,000 hectares (17,300 acres) of forest, the Bantay Bukid scheme has improved the guard presence to one person for every 200 hectares (500 acres).

With many pairs of eyes watching over the forests, it helped deter timber and wildlife poaching activities, Ibaez said, noting that the Indigenous women also benefit through livelihood projects.

Despite the successes in the field last year, the PEF has taken a financial beating from the COVID-19 pandemic, according toIbaez and Salvador. The foundation has had to appeal to the public for donations to keep its work going amid the health crisis.

Salvador said the PEFs rehabilitation center, which usually welcomes about 200,000 visitors annually, lost its main income stream as the pandemic forced it to shut to the public from March.

We lost about a third of our revenues The large chunk of conservation money came from the gate receipts of the center, he said, adding that the PEF has received the bulk of its funding from corporate and private contributors rather than from the government.

Ibaez said the center had lost some 2 million pesos (about $40,000) per month due to the lockdown.

With the pandemic still unfolding, Salvador said short-term conservation efforts for the national bird pose a big challenge.

Were [financially] crippled due to lack of resources. Until this pandemic is effectively handled, the problem of lack of resources and policies associated in curtailing this pandemic will keep us grounded and unable to respond to the needs of the eagles in the wild, he said.

But despite the debilitating impact of COVID-19 on the PEF, Salvador said the foundation will try its best to respond to the needs of the Philippine eagles in captivity and in the wild. The foundation hasnt had to lay off any of its nearly 50 workers, thanks to the continuing support of its corporate sponsors, including some of the biggest companies in the Philippines.

To help get through the COVID-19 crisis, Salvador said they have launched crowdfunding initiatives through social media, appealing to the public for help in conserving the Philippine eagles.

The rehabilitation center reopened to the public in October, operating at a limited capacity and requiring visitors to book at least 24 hours in advance. To help recover the months of losses, the center raised its entrance fee to 300 pesos ($6) and added extra activities, including a viewing of the short film Kalayaan, about a juvenile Philippine eagles journey in the wild. Visitors need to wear face masks and face shields and observe physical distancing while in the facility, in line with wider efforts to fight the spread of COVID-19.

Since we reopened our gates to the public, we have been receiving very few visitors but in some days, theres no one visiting at all, Ibaez said.

Related stories:

Banner image of Philippine eagle Balikatan (shoulder-to-shoulder) was turned over by residents in the province of Surigao last September. Balikatan has an impaired eye and could no longer be released back into the wild, making him a permanent resident of the Philippine Eagle Center in Davao City. Image courtesy of the Philippine Eagle Foundation (PEF).

FEEDBACK:Use this formto send a message to the author of this post. If you want to post a public comment, you can do that at the bottom of the page.

Read the original here:
A good year for the Philippine eagle in 2020, but not for its supporters - Mongabay.com